Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. They are building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science, and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement, and regenerative medicine.

Orbital Therapeutics

NextGen Life Sciences provides solutions in the fields of biotechnology and healthcare by offering testing equipment, reagents, kits, and instruments for medical research.

NextGen Life Sciences

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re  building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. 

Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.

Newpath Management

Andreessen Horowitz

ARCH Venture Partners

Orbital Therapeutics CSO, Dr. Gilles Besin, pictured here with Dr. Katalin Karikó, Nobel Prize Winner in Physiology or Medicine (2023), recently attended “Cracking the Code: The Dawn of Nucleic Acid Medicines” conference at Worcester Polytechnic Institute, where speakers discussed recent clinical successes, and current and upcoming challenges in the development of nucleic acid medicines! #CrackingTheCode23 #JoinOurOrbit

Do you have deep expertise successfully leading IND-enabling studies related to LNP/RNA? If so, there may be an available position open for you here at Orbital! Apply here to #JoinOurOrbit.

Congratulations to Orbital Co-Founder, Drew Weissman, on the 2023 Nobel Prize in Physiology or Medicine. Dr. Weissman and Katalin Karikó were jointly awarded the prize, “for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.” https://lnkd.in/g8-xG_b #JoinOurOrbit

We're excited to share that Orbital has been named as one of Biopharma's most promising startups in 2023! We're proud to be named to Endpoints 11. Congratulations, Orbiters! #JoinOurOrbit

Last week Orbital celebrated 1-year with a harbor cruise in San Francisco! Cheers to a great day and an even better year, Orbiters! #JoinOurOrbit

Kristen Ott's RNA Platform team here at Orbital is growing! We are looking for talented individuals with experience in both molecular biology and biochemistry to be a part of the design, production, and characterization of novel RNA molecules. Apply here! #JoinOurOrbit

Happy 1-year anniversary, Orbiters! It's been an exciting first year of defining new frontiers of science to lead the future of RNA medicines #JoinOurOrbit

With the combination of high caliber science, revolutionary technologies, a world-class team and an extraordinary team environment, Orbital is aiming to be a therapeutically transformational company. Check out some of our available openings below to #JoinOurOrbit!

https://lnkd.in/e5bfcMSy

Orbital’s CSO Gilles BESIN will be leading the discussion on Circular RNA, a RNA Platform for RNA Medicines at the mRNA Conference 2023 in Boston on August 28 – 29th! #JoinOurOrbit https://lnkd.in/eXyd4yPM

Metric
Company Name	Orbital Therapeutics	NextGen Life Sciences
Symbol
MSH ID	COM:ORBITALTX	COM:NEXTGENLIFE
Market	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country		IN
Stage
Employee Count	11
Website	orbitaltx.com	nextgenlife.com
LinkedIn	orbital-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	14.82
28-Day Growth Score	20.85
90-Day Growth Score	18.55
365-Day Growth Score	38.56

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ORBITALTX

Orbital Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue